New book by Larry Connors Click here Improve your trading - See how
Daiichi Sankyo to introduce Ranbaxy's generic drug in Japan -
Daiichi Sankyo to launch Ranbaxy's drugs in Japan soon -
FDA ISSUES TO TAKE LONG TIME TO SOLVE: INDIAN PHARMA CO RANBAXY -
DAIICHI SANKYO TO LAUNCH RANBAXY DRUGS IN JAPAN SOON -
Generic Pharmaceutical Partner Jay Deshmukh Joins Knobbe Martens D.C. Office -
Ranbaxy Laboratories sells Ranbaxy Vietnam Company -
Ranbaxy partners with Validus to sell calcium drug in US -
INDIA'S RANBAXY HAILS US COURT RULING ON VALCYTE PATENT -
CLB halts board meeting of Zenotech Laboratories -
Ranbaxy signs in-licensing agreement with Medy-Tox -
Ranbaxy Laboratories signs agreement with Medy-Tox for Neuronox -
Ranbaxy launches generic Rocaltrol -
INDIA'S RANBAXY PARTNERS WITH VALIDUS TO SELL CALCIUM DRUG IN US -
Ranbaxy, Strides surges on Tamiflu order -
ROMANIAN UNIT OF INDIA'S RANBAXY LAB TO MARKET OSTEOPOROSIS DRUG -
INDIAN COURT PULLS UP RANBAXY FOR DELAYED RAISING OF REFUND -
INDIAN DRUG MAJORS INCREASE PRODUCTION OF TAMIFLU -
Ranbaxy wins FDA approval for generic migraine drug -
Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets -
Ranbaxy wins Canadian approval for Ran-Ropinirole tablets -
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
